back to homepage

Mukowiscydoza- najnowsze wiadomości w oczekiwaniu na lek

Celtaxsys’ – Lead Pipeline Immuno-Modulator for CF Granted Orphan Drug Designation 0

Celtaxsys, Inc., a privately-owned, clinical stage drug discovery and development company focused on addressing serious inflammatory diseases, has just announced the U.S. Food and Drug Administration has granted the company’s

Read More